文献速递临床试验与 GCP

舒格利单抗联合化疗一线治疗晚期胃癌:GEMSTONE-303随机临床试验

First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

GEMSTONE-303是一项在中国54个中心开展的3期随机双盲安慰剂对照试验,纳入479例PD-L1 CPS≥5、不可切除局部晚期或转移性胃或胃食管结合部腺癌初治患者,比较舒格利单抗联合CAPOX与安慰剂联合CAPOX。舒格利单抗组中位总生存期15.6个月 vs 12.6个月(HR 0.75,P=.006),中位无进展生存期7.6个月 vs 6.1个月(HR 0.66,P<.001),安全性可控。

要点

  • 舒格利单抗联合CAPOX一线治疗PD-L1 CPS≥5晚期胃癌显著改善总生存期(HR 0.75)
  • 舒格利单抗组中位无进展生存期7.6个月,对照组6.1个月(HR 0.66)
  • ≥3级治疗相关不良事件发生率舒格利单抗组53.9%,安慰剂组50.6%

核心结论

  • 在既往未治疗的不可切除局部晚期或转移性胃或胃食管结合部腺癌患者中,舒格利单抗联合化疗显著延长总生存期和无进展生存期,安全性可控。

研究设计与样本

  • GEMSTONE-303为3期随机双盲安慰剂对照研究,在中国54个中心开展,2019年4月9日至2021年12月29日入组,随访至2023年7月9日。
  • 共随机479例PD-L1 CPS≥5、不可切除局部晚期或转移性胃或胃食管结合部腺癌、未接受过全身治疗的合格患者。
  • 患者接受舒格利单抗1200 mg静脉注射(n=241)或安慰剂(n=238),每3周一次,最长24个月,联合CAPOX每3周一次,最多6个周期。

主要发现

  • 舒格利单抗组中位随访25.1个月,安慰剂组26.3个月;两组基线特征均衡,男性分别占71.4%和74.8%。
  • 舒格利单抗组中位总生存期15.6个月(95%CI 13.3-17.8)vs 安慰剂组12.6个月(95%CI 10.6-14.1),HR 0.75(95%CI 0.61-0.92),P=.006。
  • 舒格利单抗组中位无进展生存期7.6个月(95%CI 6.4-7.9)vs 安慰剂组6.1个月(95%CI 5.1-6.4),HR 0.66(95%CI 0.54-0.81),P<.001。
  • ≥3级治疗相关不良事件发生率舒格利单抗组53.9%,安慰剂组50.6%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Gastric cancer, including gastroesophageal junction cancer, is one of the most commonly diagnosed cancers worldwide, with high mortality. Sugemalimab is a fully human anti-programmed death-ligand 1 (PD-L1) antibody. The combination of sugemalimab and chemotherapy showed promising antitumor activity and safety in a phase 1b study among patients with treatment-naive, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. This combination was further evaluated in the GEMSTONE-303 phase 3 trial. OBJECTIVE: To evaluate the efficacy of sugemalimab in combination with capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX as first-line treatment for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 combined positive score (CPS) of 5 or greater. DESIGN, SETTING, AND PARTICIPANTS: GEMSTONE 303 is a phase 3, randomized, double-blind, placebo-controlled study conducted at 54 sites in China that enrolled patients from April 9, 2019, through December 29, 2021, with follow-up to July 9, 2023. A total of 479 eligible patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS of 5 or greater who did not receive any prior systemic therapy were randomized. INTERVENTION: Patients received sugemalimab (1200 mg intravenously) (n = 241) or placebo (n = 238) every 3 weeks for up to 24 months, plus CAPOX every 3 weeks for up to 6 cycles. MAIN OUTCOMES AND MEASURES: Primary outcomes were overall survival and investigator-assessed progression-free survival. RESULTS: Baseline characteristics were well balanced between the 2 groups. Most patients were male (71.4% in sugemalimab group, 74.8% in placebo group). Median follow-up was 25.1 months in the sugemalimab group and 26.3 months in the placebo group. The sugemalimab group demonstrated significant improvements in overall survival (median, 15.6 months [95% CI, 13.3-17.8] vs 12.6 months [95% CI, 10.6-14.1]; hazard ratio, 0.75 [95% CI, 0.61-0.92]; P = .006) and progression-free survival (median, 7.6 months [95% CI, 6.4-7.9] vs 6.1 months [95% CI, 5.1-6.4]; hazard ratio, 0.66 [95% CI, 0.54-0.81]; P < .001). Grade 3 or higher treatment-related adverse events occurred in 53.9% of patients in the sugemalimab group and 50.6% in the placebo group. CONCLUSIONS AND RELEVANCE: Sugemalimab plus chemotherapy significantly prolonged overall survival and progression-free survival with a manageable safety profile in previously untreated patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03802591.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Zhang X, Wang J, Wang G, et al. First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial. JAMA. 2025. PMID: 39992668. doi:10.1001/jama.2024.28463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。